Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.45 |
| ▸ | BCR | P11274 | 6/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041102 | 0.85 | BMX (0.46) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL6041094 | 0.83 | ABL1 (0.45) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL6041090 | 0.81 | KIT (0.66) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL6041103 | 0.79 | ABL1 (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4891507 | 0.78 | PDGFRA (0.63) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL6041122 | 0.78 | LCK (0.59) | LCK | |
| SCHEMBL6041150 | 0.77 | ABL1 (0.57) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL4892458 | 0.76 | PDGFRA (0.78) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL19376721 | 0.75 | ABL1 (0.59) | ABL1PDGFRABCRPDGFRBLCK | |
| SCHEMBL19966831 | 0.73 | ABL1 (0.62) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885PDGFRA 2913/4885BCR 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.